<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02441933</url>
  </required_header>
  <id_info>
    <org_study_id>4-2015-0074</org_study_id>
    <nct_id>NCT02441933</nct_id>
  </id_info>
  <brief_title>Carboplatin in EARLY Triple Negative Breast Cancer Trial (PEARLY Trial)</brief_title>
  <official_title>A Randomized, Multicenter, Open-label, Phase III Trial Comparing Anthracyclines Followed by Taxane Versus Anthracyclines Followed by Taxane Plus Carboplatin as (Neo) Adjuvant Therapy in Patients With Triple-negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open-label, multicenter, phase III study comparing anthracyclines
      followed by taxane to anthracyclines followed by taxane plus carboplatin as (neo)adjuvant
      therapy in patients with triple-negative breast cancer.

      Patients with stage II/III operable triple-negative breast cancer are eligible. Patients who
      need adjuvant chemotherapy after breast surgery as well as patients who need neoadjuvant
      chemotherapy for TNBC are eligible.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>5-year event free survival</measure>
    <time_frame>5 year</time_frame>
    <description>time from randomization to the occurrence of the following events
: loco-regional recurrence, distant recurrence, death from any cause, contralateral invasive breast cancer, second primary cancer, and clinically inoperable and residual disease at surgery (only in the neoadjuvant population)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant recurrence free survival</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(loco-regional recurrence free survival</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pathologic complete response rate</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">840</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>carboplatin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>taxane plus carboplatin</intervention_name>
    <description>Doxorubicin (60 mg/m2) IV + cyclophosphamide (600 mg/m2) IV every 3 weeks for 4 cycles followed by taxane plus carboplatin for 4 cycles The taxane plus carboplatin regimen can be selected based on the investigator's discretion from among the following two regimens.
Docetaxel (75 mg/m2) IV plus carboplatin (AUC 5) IV every 3 weeks for 4 cycles
Paclitaxel (80 mg/m2) IV weekly for 12 doses plus carboplatin (AUC 5) IV every 3 weeks for 4 cycles</description>
    <arm_group_label>carboplatin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taxane</intervention_name>
    <description>Doxorubicin (60 mg/m2) IV + cyclophosphamide (600 mg/m2) IV every 3 weeks for 4 cycles followed by taxane for 4 cycles The taxane regimen can be selected at the investigator's discretion from among the following two regimens.
Docetaxel (75 mg/m2) IV every 3 weeks for 4 cycles
Paclitaxel (80 mg/m2) IV weekly for 12 doses</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female patients who are &gt;18 years of age

          2. ECOG 0 or 1

          3. The tumor must be invasive carcinoma of the breast on histologic examination

          4. The tumor must have been determined to be HER2-negative, as follows:

               -  IHC 0 or 1+; or

               -  IHC 2+ and ISH non-amplified, with a ratio of &lt;2.0, and if reported, an average
                  HER2 gene copy number of &lt;6 signals/cell; or

               -  ISH non-amplified without IHC

          5. The tumor must have been determined to be ER- and PR-negative, as assessed by the
             current ASCO/CAP guidelines.

          6. All of the following staging criteria (AJCC 7th edition) must be met:

               -  Lymph node-positive disease: cytologically positive in the neoadjuvant group* and
                  pathologically positive in the adjuvant group

               -  If the lymph node is cytologically or pathologically negative, the tumor size
                  must be &gt;2.0 cm (* In the neoadjuvant group, if there is evidence of suspicious
                  axillary lymph nodes at the baseline imaging study or physical examination, then
                  FNA or core biopsy is required to confirm the nodal status)

          7. The patient must have undergone either a mastectomy or lumpectomy in the adjuvant
             group

          8. The patient must have completed one of the nodal surgery procedures listed below in
             the adjuvant group:

               -  Sentinel lymph node biopsy (SLNB) alone:

        V If pathologic nodal staging based on SLNB is pN0 V If pathologic nodal staging based on
        SLNB is 1 or 2 positive nodes, the primary tumor must be T1 or T2 by pathologic evaluation
        and lumpectomy and the nodal involvement must be limited to 1 or 2 positive nodes

          -  SLNB followed by removal of additional non-sentinel LNs if the SLN is positive; or

          -  Axillary lymphadenectomy with or without SLNB (In the neoadjuvant group, if baseline
             LN NAB or core biopsy is positive, ALND should be performed) 9) LVEF assessment by
             echocardiography or MUGA scan must be &gt;50%, regardless of the cardiac imaging
             facility's lower limit of normal 10) The patient must have adequate hepatic, renal,
             and bone marrow function;

          -  Bone marrow function Hb: ≥ 10.0 g/dL ANC: ≥ 1,500/µL Platelet count: ≥ 10 × 10⁴/µL

          -  Renal function Creatinine: ≤ 1.5 × UNL or Creatine clearance (Ccr) &gt;50 ml/min by the
             Cockcroft formula

          -  Hepatic function Total Bilirubin: ≤ 1.5 × UNL AST/ALT: ≤ 2.5 × UNL 10) Ability and
             willingness to comply with the study visits, treatment, testing, and with the
             protocol, as per investigator's judgment

        Exclusion Criteria:

          1. Any prior systemic treatment for primary invasive breast cancer

          2. cT4 or pT4 tumors including inflammatory breast cancer

          3. Occult breast cancer

          4. Evidence of metastatic breast cancer

          5. Patients with second primary cancer; EXCEPTIONS: adequately treated non-melanoma skin
             cancer, curatively treated in situ cancer of the cervix, DCIS of the breast, thyroid
             cancer with a size of &lt;2 cm (papillary, follicular, and medullary type), and other
             solid tumors curatively treated with no evidence of disease for &gt;5 years prior to
             randomization.

          6. Simultaneous bilateral breast cancer

          7. Patients considered a poor medical risk due to a serious, uncontrolled medical
             disorder or uncontrolled infection.

          8. Pregnant or breastfeeding women
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chungbuk university hospital</name>
      <address>
        <city>Cheonju</city>
        <state>Chungchung Do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ki Hyeong Lee, MD, PhD</last_name>
      <email>kihlee@chungbuk.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang</city>
        <state>Gyeonggido</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keun Seok Lee, MD, PhD</last_name>
      <email>ksleemd@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Health Insurance Service Ilsan Hospital</name>
      <address>
        <city>Ilsan</city>
        <state>Gyeonggido</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soo Jung Hong, Md, PhD</last_name>
      <email>suzzy901@nhimc.or.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bundang Cha Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggido</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong Hwa Moon, MD, PhD</last_name>
      <email>ymoon@cha.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ajou universwity Medical Center</name>
      <address>
        <city>Suwon</city>
        <state>Gyeonggido</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seok Yun Kang, MD</last_name>
      <email>kangsy01@ajou.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Soonchunhyang university Cheonan hospital</name>
      <address>
        <city>Cheonan</city>
        <state>Gyungkido</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Han Jo Kim, MD</last_name>
      <email>hzmd@schmc.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inje University Haeundae Paik Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung Sook Lee, Md, PhD</last_name>
      <email>H00285@paik.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keon Uk Park, MD, PhD</last_name>
      <email>kupark@dsmc.or.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eun Kyung Cho, MD, PhD</last_name>
      <email>ekcho@gilhospital.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul national university Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Se Hyun Kim, MD</last_name>
      <email>sehyunkim@snubh.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyung Hae Jung, Md, PhD</last_name>
      <email>khjung@amc.seoul.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Hyun Park, MD</last_name>
      <email>jinhyunpak@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Catholic university of Korea, Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ji Eun Lee, MD, PhD</last_name>
      <email>befamiliar@naver.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chung Ang University Heaelthcare System</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hee Jun Kim, MD, PhD</last_name>
      <email>heejun.dino11@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hei Cheul Jeung, Md, PhD</last_name>
      <email>jeunghc1123@yuhs.ac</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Anam hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyong Hwa Park, MD, PhD</last_name>
      <email>khpark@korea.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyunghee University Healthcare System</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sun Kyung Baek, MD</last_name>
      <email>wkiki@naver.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young Hyuck Im, MD, PhD</last_name>
      <email>imyh00@skku.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yonsei Cancer Center at Yonsei University Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joo Hyuk Sohn, MD, PhD</last_name>
      <phone>82-2-2228-8130</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Su Jin Koh, MD, PhD</last_name>
      <email>sujinkoh@daum.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wonju Severance Christian Hospital</name>
      <address>
        <city>Wonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung Taek Lim, MD</last_name>
      <email>darksgtlim@naver.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2015</study_first_submitted>
  <study_first_submitted_qc>May 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2015</study_first_posted>
  <last_update_submitted>March 13, 2018</last_update_submitted>
  <last_update_submitted_qc>March 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Taxane</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

